Having proved its efficacy against COVID-19, mRNA technology is positioned to combat another insidious human adversary: cancer.
Jonathan Sharp
Advertisement
Jonathan Sharp is the Chief Financial Officer of Environmental Litigation Group, P.C. He is responsible for the firm's asset management, financial analysis, and case assessment. Since 1990, Environmental Litigation Group, P.C. has advocated for victims of harmful exposure to hazardous chemicals in the workplace.
Articles by Jonathan Sharp
Advertisement
Latest Updated Articles
mRNA Technology: First COVID-19, Now CancerPublished: October 22nd 2021 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Johnson and Johnson Reveals Plan to Separate Orthopaedics Business
2
The Most-Favored-Nation Policy: Outlook and Implications Beyond U.S.
3
Nabla Bio Enters $1 Billion Multi-Year Research Collaboration with Takeda
4
The Evolving Landscape in Psychiatry: Challenges and Opportunities for Biopharma
5
